Enfuvirtide

Medical Advocates
Enfuvirtide [T-20] (Fuzeon)

Conference Citations

14th CROI
8th Int Congress on Drug Therapy in HIV Infection
46th ICAAC
XVI International AIDS Conference
13th CROI
45th ICAAC
3rd IAS Conference
6th Int Wkshp on Clinical Pharmacology of HIV Therapy
12th CROI
44th ICAAC
XV International AIDS Conference
Conference Archives

Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Last Update: February 26, 2008

14th Conference on Retroviruses and
Opportunistic Infections

CONFERENCE PDF POSTER
Enfuvirtide Does Not Require Dose-adjustment in Patients with Chronic Renal Failure: The Results
of a Pharmacokinetic Study of Enfuvirtide in HIV-1-infected Patients with Impaired Renal Function
(NP17586)
P Tebas, N Bellos, C Lucasti, et al
PDF Poster   Abstract

CONFERENCE PDF POSTER
Lack of Placental Transfer of Enfuvirtide in an ex vivo Human Placental Cotyledon Perfusion Model
Ferreira, P Ceccaldi, B Visseaux, et al
PDF Poster    Abstract

CONFERENCE PDF POSTER
CCR5 Density Levels on Primary CD4 T Cells Affect the Replication and Enfuvirtide Susceptibility of
R5 HIV-1: Clinical Implications
A Heredia, B Gilliam, O Latinovic, et al
PDF Poster    Abstract

CONFERENCE PDF POSTER
Kinetics of Disappearance of Enfuvirtide-resistance HIV-1 Mutations after Drug Discontinuation
C Charpentier, M Jenabian, C Piketty, et al
PDF Poster    Abstract

8th Int Congress on Drug Therapy in HIV Infection

A pilot 48 week study of once daily (180mg QD) vs twice daily (90mg BID) enfuvirtide (ENF)
D Wright, A Rodriguez, E Godofsky, et al
Abstract

Injection site reactions (ISR) and success of HAART influence continued use of enfuvirtide (T20)
M Vogel, E Wolf, K Ummard, et al
Prospective study assessing injection site reactions, quality of life and enfuvirtide administration
preference using Biojector versus needles
M Loutfy, M Harris, J Raboud, et al
Enfuvirtide + NRTIs for the treatment of HIV infected patients with concurrent active mycobacterial
infection: a pilot experience
C Allavena, C Biron, M-P Cossevin, et al
Inter-country variation in physician perspectives of enfuvirtide (ENF) prescribing
R Horne, V Cooper, G Gellaitry
Abstract

Switching a toxicity-causing antiretroviral (ARV) to enfuvirtide (ENF) in patients with treatment-
limiting toxicities
M Stoll, M Muller, S Staszewski, et al
Abstract

Mitochondrial DNA (mtDNA) content in enfuvirtide-treated healthy volunteers
G Garrabou, S Lopez, V Rodriguez, et al
Abstract

Friends of Fuzeon
KF MacRae
Abstract

XVI International AIDS Conference

The mechanism of enfuvirtide resistance and structural insights into the corresponding fitness deficits
in response to the N43D resistance mutation
Bai X., Seedorff J., Wilson K., et al
Abstract

Positive patient adherence and satisfaction using a novel nursing support program as part of enfuvirtide
therapy
Sweeney E., Johnson N., DeSpirito M., Greer B.
Abstract

A nonrandomized large prospective evaluation of alternative injection devices (Biojector� 2000 (B2000),
standard needles/syringes, or insulin needles/syringes) for enfuvirtide (ENF) in a national community-
based specialty pharmacy
Tschida S., Zappa A., Godwin M.
Abstract

Evolution of genotyping and phenotyping resistance to enfuvirtide in HIV-infected patients with persistent
viraemia, during and after treatment
Trabaud M.-A., Cotte L., Labernardi�re J.L., et al
Abstract

New fusion inhibitor peptides, TRI-999 and TRI-1144, are potent inhibitors of enfuvirtide and T-1249
resistant isolates
Davison D.K., Medinas R.J., Mosier S.M., et al
Abstract

Currently marketed nucleos(t)ides provide only marginal additional viral load (VL) suppression to
regimens including enfuvirtide (ENF) and boosted PIs (PI/r) in triple class experienced patients
(TEPs)
DeMasi R., Thommes J., Graham N.
Abstract

Multidisciplinary care of HIV-infected patients treated with enfuvirtide (Fuzeon�)
Darque A., Falaschi L., Schlouch B., et al
Abstract

Quality of life (Qol) and tolerability after administration of enfuvirtide (ENF) with a 31-Gauge,
thin-walled, 8mm needle (QUALITE study)
Shalit P., True A., Thommes J.
Abstract

CD4 increases in patients with ongoing viral replication while receiving enfuvirtide are associated with
V38 and other mutations in gp41
Melby T., DeSpirito M., Demasi R., et al
Abstract

Discontinuation of enfuvirtide after long-term administration in HIV-1-infected patients � the Swiss
HIV cohort study (SHCS)
Elzi L., Kaufmann G., Weber R., et al
Abstract Abstract

13th Conference on Retroviruses and
Opportunistic Infections

Liver Transplantation in HIV-co-infected Patients Treated by Enfuvirtide
E Teicher, D Vittecoq, A M Taburet, et al
Abstract

< in vivo Fitness of Enfuvirtide-resistant HIV-1 Estimated by Allele-specific PCR during Partial
Treatment Interruption and Pulse Intensification
Vi Marconi, S Bonhoeffer, R Paredes, et al
Abstract

Continued GP41 Evolution after Interruption of Enfuvirtide: Evidence for Ongoing Immunologic
Pressure in Advanced HIV Disease
C Kitchen, M Suchard, J Lu, et al
S Fransen, J Whitcomb, T Wrin, et al
Abstract

POSTER
Unexpected Drug-Drug Interaction between Tipranavir/Ritonavir and Enfuvirtide
D Gonzalez De Requena, A Calcagno, S Bonora, et al
PDF Poster      Abstract

HIV-1 Co-receptor Tropism in Triple-class-experienced Patients: Baseline Correlates and
Relationship to Enfuvirtide Response